In the News

04 May 2011 | HFMWeek

Lionel Melka on Actelion's position

HFMWeek Daily Snapshot

Actelion, the Swiss drugmaker locked in a boardroom battle with hedge funds, may get its wish and remain independent for the moment, writes Bloomberg. Potential suitors like Amgen and Bristol-Myers Squibb would probably wait until the results of a clinical test confirm a successor to the best-selling lung medicine Tracleer works, said Lionel Melka, co-manager of Paris-based Bernheim, Dreyfus & Co.’s Diva Synergy Fund, which holds Actelion stock.

04 May 2011 | Bloomberg

Lionel Melka discusses Actelion's position

Actelion May Keep Suitors at Bay a Little Longer With Drug Test

“I don’t think they’ll be bought before the end of the year,” Melka said in a telephone interview. “No bidder would put that amount of money on the table when there’s such a big question mark.”

21 April 2011 | Thomson Reuters

Lionel Melka on Astra Zeneca's position

ANALYSIS-Funds prefer GSK to Astra as growth paths diverge

"AstraZeneca's equity story is now at a crossroads and can be compared with Sanofi's situation last year. They could endorse a transforming M&A deal to plug their pipeline hole and keep a growth stock status," said Lionel Melka, co-manager of Bernheim, Dreyfus & Co's Diva Synergy Fund.

12 April 2011 | eFinancialCareers.fr

Bernheim, Dreyfus & Co in the news

Paris, Londres, Genève : où conseilleriez-vous Guillaume Rambourg et Roger Guy de lancer leur hedge fund ?

Des gérants ont déjà franchi le pas… comme les cofondateurs de Bernheim, Dreyfus & Co, Amit Shabi et Lionel Melka, qui ont rapatrié fin 2009 leur hedge fund à Paris, après trois ans d’histoire suisse.

10 11 12 13 14 15 16 17 |  18 |  19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34